Table 1. GCC status in esophageal, gastric, and pancreatic cancers.
| GCC status | Cancer types | ||||||
|---|---|---|---|---|---|---|---|
| Esophageal cancers | Gastric cancers (n = 276) | Pancreatic cancers | |||||
| Primary | Metastatic | ||||||
| Squamous cell (n = 130) |
Adenocarcinoma (n = 156) |
Signet ring (n = 11) |
Undifferentiated (n = 13) | Adenocarcinoma (n = 96) | Adenocarcinoma (n = 136) |
||
| GCC negative, n (%) | 53 (41) | 38 (24) | 1 (9) | 4 (31) | 45 (47) | 49 (36) | |
| GCC positive | Total, n (%) | 77 (59) | 118 (76) | 10 (91) | 9 (69) | 51 (53) | 87 (64) |
| Cytoplasmic, n (%) | 77 (59) | 47 (30) | 9 (82) | 9 (69) | 15 (16) | 35 (26) | |
| Membranous-apical, n (%) | 0 (0) | 13 (8) | 0 (0) | 0 (0) | 14 (15) | 12 (9) | |
| Cytoplasmic + membranous-apical, n (%) | 0 (0) | 58 (37) | 1 (9) | 0 (0) | 22 (23) | 40 (29) | |
The table reports the numbers of cases with respective GCC status. Percentages are shown in parentheses. The pattern of expression is defined by the numbers of cases with distinct areas in tumor cells that show GCC-positive staining in membranous-apical, cytoplasmic, or both areas.
GCC, guanylyl cyclase-C.